Life Extension Update
Lower risk of dying from any cause over 4.64 year median follow-up period in prostate cancer patients who used metformin
Tuesday, August 13, 2013. In an article published online on August 5, 2013 in the Journal of Clinical Oncology, researchers from Toronto report a lower risk of mortality among prostate cancer patients with diabetes who were being treated with the antidiabetic drug metformin in comparison with those who were not being treated with the drug.
David Margal, MD, PhD at the University of Toronto and his associates evaluated information from 3,837 men with prostate cancer aged 66 years and older identified by the Ontario Diabetes Database. An additional database provided information on antidiabetic medications prescribed to the subjects. There were 1,343 deaths over a 4.64 year median follow-up from the time of diagnosis, among which 291 were caused by prostate cancer.
Metformin was used by 32.6% of the men prior to prostate cancer diagnosis and 42.2% following diagnosis. For each six months of metformin use after diagnosis, there was a 24% reduction in the risk of dying from prostate cancer in comparison with nonusers. There was also a 24% reduction in the risk of death from any cause during the first six months of metformin use, which declined to a 7% reduction with longer use. The authors note that metformin was associated with a benefit regardless of cancer treatments being used; which implies that metformin could help improve survival as an adjunct therapy.
Dr Margal and his coauthors suggest that metformin may reduce the risk of dying from prostate cancer by preventing cancer progression. The drug may influence cancer cells indirectly by reducing insulin levels or directly by affecting the proliferation of cancer cells and apoptosis (programmed cell death). "Because prostate cancer is a slow-growing disease, medication exposures postdiagnosis may have an impact on disease progression and survival and thus may be ideal for secondary prevention strategies," they write.
"Our study is among the first to report that cumulative metformin use after prostate cancer diagnosis is associated with improved all-cause and prostate cancer-specific survival among elderly diabetic men," they announce. "We believe an interventional study of the use of metformin to delay progression in prostate cancer is warranted."
This supplement should be taken in conjunction with a healthy diet and regular exercise program. Individual results are not guaranteed and results may vary.
The information provided on this site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem. You should not stop taking any medication without first consulting your physician.
If you are not 100% satisfied with any purchase made directly from Life Extension®, just return your purchase within 12 months of original purchase date and we will either replace the product for you, credit your original payment method or credit your Life Extension account for the full amount of the original purchase price (less shipping and handling).
These statements have not been evaluated by the Food and Drug Administration.
These products are not intended to diagnose, treat, cure, or prevent any disease.